Early 1990s—David Lisonbee begins his personal quest for optimal immune system support.

1997—David unearths research on transfer factors.

1998—David and Bianca Lisonbee harness decades of research to introduce 4Life Transfer Factor® to the world through network marketing.

1999—4Life advances transfer factor technology to produce the first 4Life® Transfer Factor Plus® product formulation.

2002—4Life launches the first Targeted Transfer Factor® product, featuring the exclusive egg-sourced transfer factor patent (U.S. Patent #6,468,534).

2003—4Life Transfer Factor is first featured in the Physicians’ Desk Reference for Nonprescription Drugs, Dietary Supplements, and Herbs, the standard reference guide for medical professionals across the United States.

2004—4Life introduces the 4Life Transfer Factor® Advanced Formula products, combining transfer factors from cow colostrum and chicken egg yolk. 4Life patented the combination process the following year (U.S. Patent #6,866,868).

2004—The Russian Academy of Medical Sciences releases a letter encouraging health care professionals in Russia to use 4Life Transfer Factor products in their protocols.

2005—4Life launches 4Life Transfer Factor® RioVida®.

2006—David Lisonbee receives the Russian I.N. Blokhina award in honor of his commitment to transfer factor research, patents, and innovative production methods.

2006—TotalHealth magazine publishes an in-depth report on the developments of transfer factors and cites the work of David Lisonbee and 4Life Research in the field.

2007—4Life discovers immune activity in nanofraction molecules and introduces 4Life Transfer Factor® Tri-Factor® Formula.

2009—4Life launches 4Life Transfer Factor® RioVida Burst® Tri-Factor® Formula.

2010—4Life introduces the sixth and seventh Targeted Transfer Factor products—4Life® NanoFactor® Glutamine Prime® and 4Life Transfer Factor® KBU™.

2011—4Life secures a composition patent for 4Life Transfer Factor® Cardio (U.S. Patent #7,815,943).